Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 8, 2013, Pages 1001-1007

  Campo, P ^a   Ayuso, P ^a   Salas, M ^a   Plaza, M C ^a   Cornejo Garcia J A ^a   Dona I ^a   Torres, M J ^a   Blanca Lopez N ^b   Canto, G ^b   Gueant J L ^c   Sanak, M ^d   Blanca, M ^a,c  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c INSERM   (France)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

aspirin exacerbated cutaneous disease; inflammatory mediators; lysine nasal challenge; multiple nonsteroidal anti inflammatory drug induced urticaria angioedema; nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; DIPYRONE; IBUPROFEN; IMMUNOGLOBULIN E ANTIBODY; LYSINE; PROSTAGLANDIN E2; TRYPTASE;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; EOSINOPHIL; HUMAN; MAJOR CLINICAL STUDY; MEDIATOR RELEASE; NASAL LAVAGE; NOSE PROVOCATION TEST; PHENOTYPE; PRIORITY JOURNAL;

ASPIRIN-EXACERBATED CUTANEOUS DISEASE; INFLAMMATORY MEDIATORS; LYSINE NASAL CHALLENGE; MULTIPLE NONSTEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED URTICARIA/ANGIOEDEMA; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; RESPIRATORY HYPERSENSITIVITY; URTICARIA; YOUNG ADULT;

EID: 84883182535     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12187     Document Type: Article

References (38)

1. Cornejo-García JA, Blanca-Lõpez N, Doña I, Andreu I, Agúndez JA, Carballo M, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab 2009; 10: 971-980.
2. Doña I, Blanca-Lopez N, Torres MJ, García-Campos J, García-Núñez I, Gõmez F, et al. Drug hypersensitivity reactions: patterns of responses, drug involved and temporal variation in a large series of patients evaluated. J Investig Allergol Clin Immunol 2012; 22: 363-371.
3. Doña I, Blanca-Lõpez N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy 2011; 41: 86-95.
4. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDS)- classification, diagnosis and Management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011; 66: 818-829.
5. Szczeklik A, Nizankowska E, Sanak M,. Hypersensitivity to aspirin and non-steroidal anti-inflammatory drugs. In:, Adkinson NF, Bochner BS, Busse WW, Holgate S, Lemanske RF, Simons FE, editors. Middletons Allergy, Principles and Practice, 7th edn. Philadelphia: Mosby, 2009: 1227-1243.
6. Sanchez-Borges M,. NSAIDS Hypersensitivity Respiratory, Cutaneous, and Generalized Anaphylactic Symptoms. Med Clin North Am 2010; 94: 853-863.
7. Stevenson DD, Sánchez-Borges M, Szczeklik A,. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001; 87: 177-180.
8. Stevenson DD, Szczeklik A,. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118: 773-786.
9. Mayorga C, Torres MJ, Fernandez J, Canto G, Blanca M,. Cutaneous symptoms in drug allergy: what have we learnt? Curr Opin Allergy Clin Immunol 2009; 9: 431-436.
10. Kupczyk M, Kurmanowska Z, Kupryś-Lipińska I, Bocheńska-Marciniak M, Kuna P,. Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge. Respir Med 2010; 104: 1404-1409.
11. Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M,. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26: 807-814.
12. Lee DK, Haggart K, Lipworth BJ,. Reproducibility of response to nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Ann Allergy Asthma Immunol 2004; 93: 185-188.
13. Alonso-Llamazares A, Martinez-Cõcera C, Domínguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M,. Mesa del Castillo M. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002; 57: 632-635.
14. Casadevall J, Ventura PJ, Mullol J, Picado C,. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55: 921-924.
15. González-Pérez R, Poza-Guedes P, Vives-Conesa R,. The nose as a target organ in the diagnosis of severe aspirin-exacerbated respiratory disease. Am J Rhinol Allergy 2011; 25: 166-169.
16. Milewski M, Mastalerz L, Nizankowska E, Szczeklik A,. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998; 101: 581-586.
17. Tomaz EM, Ferreira MF, Spínola MA, Oliveira ML, Clode MH, Palma-Carlos AG,. Nasal provocation tests in the diagnosis of urticaria induced by acetylsalicylic acid. Allergy Asthma Proc 1997; 18: 319-322.
18. Wismol P, Putivoranat P, Buranapraditkun S, Pinnobphun P, Ruxrungtham K, Klaewsongkram J,. The values of nasal provocation test and basophil activation test in the different patterns of ASA/NSAIDS hypersensitivity. Allergol Immunopathol (Madr) 2012; 40: 156-163.
19. Blanca-Lopez N, Doña I, Torres MJ, Campo P, Rondõn C, Seoane M, et al. Value of the clinical history in the diagnosis of urticaria /angioedema induced by NSAIDS with cross-intolerance. Clin Exp Allergy 2013; 43: 85-91.
20. Dreborg S, Frew A,. EAACI Position Paper: allergen Standardization and skin tests. Allergy 1993; 48: 49-54.
21. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation test for diagnosis of aspirin hypersensitivity. Allergy 2007; 62: 1111-1118.
22. Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF Jr, Meyers DA, Norman PS, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128: 597-602.
23. Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A,. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 2011; 127: 1141-1147.
24. Blanca M, Thong B,. Progress in understanding hypersensitivity drug reactions: an overview. Curr Opin Allergy Clin Immunol 2012; 12: 337-340.
25. Caimmi S, Caimmi D, Bousquet P-J, Demoly P,. How can we better classify NSAIDS hypersensitivity reactions? Validations from a large database. Int Arch Allergy Immunol 2012; 59: 306-312.
26. Messaad D, Sahla H,. Benahmed s, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004; 140: 1001-1006.
27. Kupczyk M, Antczak A, Kuprys-Lipinska I, Kuna P,. Lipoxin A4 generation is decreased in aspirin-sensitive patients in lysine-aspirin nasal challenge in vivo model. Allergy 2009; 64: 1746-1752.
28. Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Bienkiewicz B, Kowalski ML,. Involvement of 15-lipoxygenase and prostaglandin EP receptors in aspirin-triggered 15-hydroxyeicosatetraenoic acid generation in aspirin-sensitive asthmatics. Clin Exp Allergy 2008; 38: 1108-1116.
29. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A,. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008; 63: 27-34.
30. Gaber F, Daham K, Higashi A, Higashi N, Gulich A, Delin I, et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63: 1076-1082.
31. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A,. Histological spectrum of cutaneous reactions to aspirin in chronic idiopathic urticaria. J Cutan Pathol 2004; 31: 323-329.
32. Sánchez-Borges M, Fernández-Caldas E, Capriles-Hulett A, Caballero-Fonseca F,. Mite-induced inflammation: more than allergy. Allergy Rhinol 2012; 3: e25-e29.
33. Mastalerz L, Sanak M, Kumik J, Gawlewicz-Mroczka A, Celejewska-Wojcik N, Cmiel A, et al. Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study. J Allergy (Cairo) 2012; 2012: 696792. doi: 10.1155/2012/696792.
34. Gray PA, Warner TD, Vojnovic I, Del Soldato P, Parikh A, Scadding GK, et al. Effects of non-steroidal, anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin sensitive asthmatics versus healthy donors. Br J Pharmacol 2002; 137: 1031-1038.
35. Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS,. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010; 10: 280-290.
36. Cheong HS, Park SM, Kim MO, Park JS, Lee JY, Byun JY, et al. Genome-wide methylation profile of nasal polyps: relation to aspirin hypersensitivity in asthmatics. Allergy 2011; 66: 637-644.
37. Cornejo-García JA, Jagemann LR, Blanca-Lõpez N, Doña I, Flores C, Guéant-Rodríguez RM, et al. Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. Clin Exp Allergy 2012; 42: 1772-1781.
38. Kim SH, Hur GY, Park HS,. Pharmacogenetics of aspirin-intolerant asthma. Pharmacogenomics 2008; 9: 85-91.